By David Gross
CAR-T and CAR-NK drug developers have extensive and sensitive manufacturing requirements, which often requires taking relatively large amounts of space in expensive markets. Vor is the latest company in the sector to add to its footprint, more than doubling its presence at Longfellow Partners’ 100 CambridgePark Drive facility from 33,000 square feet to approximately 76,000 square feet. The building is located near the Alewife T stop in Cambridge.
Vor is adding over 30,000 square feet on the 3rd floor of the building and over 10,000 feet on the 1st floor. It is paying nearly $68 a foot for the 3rd floor and $85 a foot on the 1st floor. It will use the space for a cGMP compliant, in house clinical manufacturing site for its CAR-T and Hematopoietic Stem Cell (HSC) candidates intended to treat Acute Myeloid Leukemia (AML).
Longfellow Partners acquired 100 CambridgePark Drive in 2017 and converted it from lab to office. Other tenants in the building include Trillium Therapeutics and Moda Labs. In total, Longfellow is converting 600,000 square feet across three buildings within a development on CambridgePark Drive. Alewife is five stops further from Boston than Kendall Square, with lab rents that are about 1/3rd cheaper.